FOLR1 and ovarian cancer: The GLORIOSA trial (NCT05445778) is an ongoing randomized Phase III study evaluating mirvetuximab plus bevacizumab as maintenance therapy in patients with platinum-sensitive ovarian cancer and high FRα expression, aiming to prolong progression-free survival compared to bevacizumab alone [19].